Masimo Corp
NASDAQ:MASI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (52.3), the stock would be worth $-152.11 (185% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -61.4 | $178.51 |
0%
|
| 3-Year Average | 52.3 | $-152.11 |
-185%
|
| 5-Year Average | 53.5 | $-155.55 |
-187%
|
| Industry Average | 27.6 | $-80.23 |
-145%
|
| Country Average | 22.9 | $-66.5 |
-137%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$9.3B
|
/ |
Jan 2026
$-151.5m
|
= |
|
|
$9.3B
|
/ |
Dec 2026
$314.9m
|
= |
|
|
$9.3B
|
/ |
Dec 2027
$353.3m
|
= |
|
|
$9.3B
|
/ |
Dec 2028
$396.8m
|
= |
|
|
$9.3B
|
/ |
Dec 2029
$396.8m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Masimo Corp
NASDAQ:MASI
|
9.3B USD | -61.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 56.2 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 25.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 36.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 22.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 42.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 18.2 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 41.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 23.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 20.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Masimo Corp
Glance View
Masimo Corp., a pioneering force in noninvasive monitoring technologies, was founded in 1989 by Joe Kiani, who envisioned a healthcare landscape imbued with precision and accessibility. The company rose to prominence with its innovative pulse oximetry technology, a tool crucial for measuring oxygen levels in patients' blood. Unlike traditional methods, Masimo's technology utilizes proprietary signal extraction techniques that allow it to deliver accurate readings even in challenging conditions such as movement or low perfusion. This innovation not only revolutionized patient monitoring but also secured Masimo significant market share within hospitals and healthcare facilities worldwide. Their devices, known for their reliability, feed into a recurring revenue model, as hospitals and medical professionals constantly require new sensors and related consumables to operate the equipment effectively. In addition to pulse oximetry, Masimo has skillfully expanded its portfolio to encompass advanced monitoring systems such as those measuring brain function and hydration levels, offering a comprehensive suite of solutions for enhanced patient care. They have ventured into consumer health as well, with devices that allow people to monitor their health metrics at home. This broadening of scope positions Masimo as a versatile player across both professional and consumer markets. By continually investing in research and development, Masimo aims to address unmet clinical needs and open new revenue streams, thus sustaining its growth trajectory in the competitive landscape of medical technology. Through strategic partnerships and acquisitions, the company has consistently augmented its capabilities, solidifying a robust financial performance anchored in its commitment to innovation and quality.